D. E. Shaw & Co., Inc. Sigilon Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.74 - $1.64 $30,676 - $67,986	-41,455 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.24 - $3.03 $5,935 - $14,504	-4,787 Reduced 10.35%	41,455 $61,000
Q4 2021 Feb 14, 2022	BUY	$2.58 - $6.13 $119,304 - $283,463	46,242 New	46,242 $128,000
Q3 2021 Nov 15, 2021	SELL	$4.42 - $10.61 $63,842 - $153,250	-14,444 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.15 - $20.17 $132,162 - $291,335	14,444 New	14,444 $155,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.